Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study.

Br J Cancer · 2005 · PMC2361663 · PMID 16222322

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

slightly significantno p-value reported

The recently published results of the X-ACT trial showed a slightly significant advantage in terms of 3 years risk of relapse (HR=0.87, CI 0.75–1.00) and of death (HR=0.84, CI 0.69–1.01) for patients treated with adjuvant capecitabine with respect to those treated with standard 5FU-FA ( Twelves et al , 2005 ).

also in 1,756 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.